LON:MDC - Mediclinic International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 355
  • Forecasted Upside: 11.22 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 319.20
▼ -1.2 (-0.37%)

This chart shows the closing price for MDC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mediclinic International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDC

Analyst Price Target is GBX 355
▲ +11.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Mediclinic International in the last 3 months. The average price target is GBX 355, with a high forecast of GBX 370 and a low forecast of GBX 340. The average price target represents a 11.22% upside from the last price of GBX 319.20.

This chart shows the closing price for MDC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Mediclinic International.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/10/2021BarclaysBoost Price TargetOverweightGBX 365 ➝ GBX 370
8/26/2021HSBCUpgradeBuyGBX 280 ➝ GBX 340
7/22/2020BarclaysReiterated RatingEqual weight
7/8/2020Jefferies Financial GroupLower Price TargetBuyGBX 482 ➝ GBX 323
6/11/2020UBS GroupDowngradeNeutralGBX 400 ➝ GBX 320
5/14/2020HSBCUpgradeHoldGBX 270 ➝ GBX 260
4/14/2020HSBCLower Price TargetReduceGBX 310 ➝ GBX 270
1/21/2020Jefferies Financial GroupBoost Price TargetBuyGBX 457 ➝ GBX 482
12/18/2019BarclaysBoost Price TargetEqual weightGBX 360 ➝ GBX 400
11/29/2019Jefferies Financial GroupBoost Price TargetBuyGBX 422 ➝ GBX 457
11/26/2019UBS GroupDowngradeNeutralGBX 385 ➝ GBX 400
11/15/2019Jefferies Financial GroupReiterated RatingBuy
10/14/2019UBS GroupReiterated RatingBuyGBX 395 ➝ GBX 385
6/20/2019HSBCLower Price TargetHoldGBX 360 ➝ GBX 310
6/7/2019UBS GroupReiterated RatingBuyGBX 410 ➝ GBX 395
6/4/2019Bank of AmericaUpgradeNeutral
4/12/2019BarclaysLower Price TargetEqual weightGBX 460 ➝ GBX 410
1/16/2019HSBCLower Price TargetHoldGBX 390 ➝ GBX 360
1/7/2019JPMorgan Chase & Co.UpgradeOverweightGBX 480 ➝ GBX 394
10/25/2018HSBCUpgradeHoldGBX 540 ➝ GBX 390
10/18/2018BarclaysDowngradeEqual weightGBX 660 ➝ GBX 460
10/2/2018CitigroupUpgradeBuy
9/28/2018BarclaysLower Price TargetOverweightGBX 700 ➝ GBX 660
8/9/2018Credit Suisse GroupLower Price TargetNeutralGBX 660 ➝ GBX 550
8/7/2018BarclaysLower Price TargetOverweightGBX 751 ➝ GBX 700
4/13/2018BarclaysInitiated CoverageOverweightGBX 751
2/2/2018BarclaysInitiated CoverageOverweightGBX 751
1/30/2018UBS GroupDowngradeNeutralGBX 600 ➝ GBX 650
12/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 695
11/30/2017Jefferies Financial GroupUpgradeBuyGBX 550 ➝ GBX 616
11/21/2017CitigroupReiterated RatingNeutral
11/20/2017Credit Suisse GroupLower Price TargetNeutralGBX 783 ➝ GBX 630
10/27/2017Jefferies Financial GroupReiterated RatingUnderperformGBX 550
10/26/2017Credit Suisse GroupBoost Price TargetNeutralGBX 265 ➝ GBX 305
10/26/2017MacquarieReiterated RatingNeutralGBX 660
10/24/2017CitigroupReiterated RatingNeutral
10/20/2017MacquarieLower Price TargetNeutralGBX 760 ➝ GBX 660
10/19/2017JPMorgan Chase & Co.DowngradeNeutralGBX 898 ➝ GBX 733
10/18/2017CitigroupLower Price TargetNeutralGBX 790 ➝ GBX 720
9/25/2017Jefferies Financial GroupLower Price TargetUnderperformGBX 650 ➝ GBX 550
7/21/2017Credit Suisse GroupReiterated RatingNeutral
6/29/2017Morgan StanleyDowngradeEqual WeightGBX 825 ➝ GBX 775
6/27/2017CitigroupReiterated RatingNeutralGBX 790
6/26/2017InvestecDowngradeHoldGBX 775
6/1/2017Jefferies Financial GroupBoost Price TargetUnderperformGBX 646 ➝ GBX 650
5/5/2017MacquarieBoost Price TargetNeutralGBX 760 ➝ GBX 790
4/28/2017InvestecReiterated RatingBuy
4/11/2017MacquarieLower Price TargetNeutralGBX 770 ➝ GBX 760
4/11/2017CitigroupReiterated RatingNeutral
4/4/2017MacquarieDowngradeNeutralGBX 860 ➝ GBX 770
2/24/2017UBS GroupDowngradeNeutralGBX 900 ➝ GBX 810
2/23/2017Credit Suisse GroupLower Price TargetOutperformGBX 1,045 ➝ GBX 985
2/22/2017CitigroupLower Price TargetNeutralGBX 890 ➝ GBX 860
2/20/2017Jefferies Financial GroupDowngradeUnderperformGBX 639 ➝ GBX 658
2/3/2017MacquarieUpgradeOutperformGBX 830 ➝ GBX 860
12/15/2016Jefferies Financial GroupLower Price TargetHoldGBX 741 ➝ GBX 639
11/29/2016Jefferies Financial GroupLower Price TargetHoldGBX 812 ➝ GBX 741
11/23/2016MacquarieLower Price TargetNeutralGBX 970 ➝ GBX 830
11/21/2016UBS GroupLower Price TargetBuyGBX 1,100 ➝ GBX 995
11/11/2016Credit Suisse GroupLower Price TargetOutperformGBX 1,120 ➝ GBX 1,045
9/28/2016Jefferies Financial GroupLower Price TargetHoldGBX 833 ➝ GBX 812
9/22/2016Jefferies Financial GroupLower Price TargetHoldGBX 920 ➝ GBX 833
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Mediclinic International logo
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 hospitals, 2 day case clinics, 3 outpatient clinics, and 110 theatres with approximately 1,893 inpatient beds in Switzerland; 52 hospitals, 10 day case clinics, 8 sub-acute hospitals, and 305 theatres in South Africa and Namibia with approximately 8,792 inpatient beds; and 7 hospitals, 2 day case clinics, 18 outpatient clinics, and 38 theatres with approximately 927 inpatient beds in the United Arab Emirates. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
Read More

Today's Range

Now: GBX 319.20
Low: 314.20
High: 328.60

50 Day Range

MA: GBX 295.33
Low: 275.80
High: 321.80

52 Week Range

Now: GBX 319.20
Low: 257.60
High: 349

Volume

747,778 shs

Average Volume

513,974 shs

Market Capitalization

£2.35 billion

P/E Ratio

34.70

Dividend Yield

3.12%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mediclinic International?

The following Wall Street analysts have issued reports on Mediclinic International in the last year: Barclays PLC, and HSBC Holdings plc.
View the latest analyst ratings for MDC.

What is the current price target for Mediclinic International?

2 Wall Street analysts have set twelve-month price targets for Mediclinic International in the last year. Their average twelve-month price target is GBX 355, suggesting a possible upside of 11.2%. Barclays PLC has the highest price target set, predicting MDC will reach GBX 370 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of GBX 340 for Mediclinic International in the next year.
View the latest price targets for MDC.

What is the current consensus analyst rating for Mediclinic International?

Mediclinic International currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDC will outperform the market and that investors should add to their positions of Mediclinic International.
View the latest ratings for MDC.

What other companies compete with Mediclinic International?

How do I contact Mediclinic International's investor relations team?

Mediclinic International's physical mailing address is 6th Floor 65 Gresham Street, LONDON, EC2V 7NQ, United Kingdom. The company's listed phone number is +44-20-79549600. The official website for Mediclinic International is www.mediclinic.com.